PL2248826T3 - Przeciwciało skierowane przeciwko PcrV - Google Patents

Przeciwciało skierowane przeciwko PcrV

Info

Publication number
PL2248826T3
PL2248826T3 PL09701235T PL09701235T PL2248826T3 PL 2248826 T3 PL2248826 T3 PL 2248826T3 PL 09701235 T PL09701235 T PL 09701235T PL 09701235 T PL09701235 T PL 09701235T PL 2248826 T3 PL2248826 T3 PL 2248826T3
Authority
PL
Poland
Prior art keywords
directed against
antibody directed
against pcrv
pcrv
antibody
Prior art date
Application number
PL09701235T
Other languages
English (en)
Inventor
Yoshito Numata
Yoshinori Yamano
Takafumi Sato
Toshinaga Tsuji
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PL2248826T3 publication Critical patent/PL2248826T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL09701235T 2008-01-10 2009-01-08 Przeciwciało skierowane przeciwko PcrV PL2248826T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008003214 2008-01-10
PCT/JP2009/050118 WO2009088032A1 (ja) 2008-01-10 2009-01-08 ＰｃｒＶに対する抗体
EP09701235.5A EP2248826B1 (en) 2008-01-10 2009-01-08 Antibody directed against pcrv

Publications (1)

Publication Number Publication Date
PL2248826T3 true PL2248826T3 (pl) 2013-11-29

Family

ID=40853144

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09701235T PL2248826T3 (pl) 2008-01-10 2009-01-08 Przeciwciało skierowane przeciwko PcrV

Country Status (13)

Country Link
US (1) US8501179B2 (pl)
EP (2) EP2248826B1 (pl)
JP (1) JP4766716B2 (pl)
KR (1) KR101259239B1 (pl)
CN (1) CN102137870B (pl)
AU (1) AU2009203426C1 (pl)
BR (1) BRPI0906810A2 (pl)
CA (1) CA2711863C (pl)
EA (1) EA020544B1 (pl)
ES (1) ES2426093T3 (pl)
PL (1) PL2248826T3 (pl)
PT (1) PT2248826E (pl)
WO (1) WO2009088032A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009203426C1 (en) 2008-01-10 2012-05-31 Shionogi & Co., Ltd. Antibody directed against PcrV
DK2407537T6 (en) 2009-03-11 2015-07-27 Shionogi & Co PcrV HUMANIZED ANTIBODY WITH ACTIVITY ANTIPSEUDOMONAL
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
US10597439B2 (en) * 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
MX2014010495A (es) * 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
BR112021023335A2 (pt) 2019-06-11 2022-01-04 Regeneron Pharma Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof
EP4735478A1 (en) 2023-06-28 2026-05-06 Universität zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU7949394A (en) 1993-11-19 1995-06-06 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
CA2318536C (en) * 1998-11-25 2009-11-17 Mcw Research Foundation, Inc. Method of and compositions for immunization with the pseudomonas v antigen
US20030228324A1 (en) * 1999-05-06 2003-12-11 Malcolm Andrew J. Peptide compositions and methods of producing and using same
EP1353688B1 (en) * 2001-01-26 2006-12-06 MCW Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
JPWO2007114340A1 (ja) * 2006-03-30 2009-08-20 明治製菓株式会社 緑膿菌の外膜タンパク質ｐａ０４２７
CN101002947B (zh) * 2007-01-16 2010-08-25 湖南农业大学 一种用于细菌病治疗的靶向药物及其制备方法
WO2009005040A1 (ja) * 2007-06-29 2009-01-08 Meiji Seika Kaisha Ltd. 緑膿菌の外膜タンパク質pa4710
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
AU2009203426C1 (en) 2008-01-10 2012-05-31 Shionogi & Co., Ltd. Antibody directed against PcrV
DK2407537T6 (en) * 2009-03-11 2015-07-27 Shionogi & Co PcrV HUMANIZED ANTIBODY WITH ACTIVITY ANTIPSEUDOMONAL

Also Published As

Publication number Publication date
US20110150896A1 (en) 2011-06-23
EA201070826A1 (ru) 2011-04-29
EP2599792A1 (en) 2013-06-05
EP2248826A1 (en) 2010-11-10
US8501179B2 (en) 2013-08-06
JP4766716B2 (ja) 2011-09-07
JPWO2009088032A1 (ja) 2011-05-26
KR20100103675A (ko) 2010-09-27
EP2248826A4 (en) 2011-03-02
AU2009203426B2 (en) 2011-11-24
CA2711863A1 (en) 2009-07-16
ES2426093T3 (es) 2013-10-21
EA020544B1 (ru) 2014-12-30
CA2711863C (en) 2014-06-10
AU2009203426C1 (en) 2012-05-31
AU2009203426A1 (en) 2009-07-16
KR101259239B1 (ko) 2013-04-29
WO2009088032A1 (ja) 2009-07-16
CN102137870A (zh) 2011-07-27
EP2248826B1 (en) 2013-06-12
CN102137870B (zh) 2014-09-03
PT2248826E (pt) 2013-09-06
BRPI0906810A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
IL276622A (en) Antibody formulation
HRP20181868T1 (hr) Anti-cmet antitijelo
ZA201102119B (en) Improved antibody libraies
GB0821100D0 (en) Antibodies
SI2146745T1 (sl) Penta-specifično protitelo
IL208045A0 (en) Antibody against the csf-1r
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
GB0708002D0 (en) Antibodies
IL210903A0 (en) Anit-il-12/il-23 antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
IL205073A0 (en) Anti-bst2 antibody
GB0718737D0 (en) Antibodies
ZA201007976B (en) Anti-pirb antibodies
EP2248826A4 (en) AGAINST PCRV TARGETED ANTIBODY
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
EP2264071A4 (en) ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody
GB0819113D0 (en) An antibody
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies
HK1146067A (en) Anti-tyrp1 antibodies
GB0804686D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody